Deep-going analysis demonstrated that neither combining crizotinib with afatinib nor MET knockdown had effects on phosphorylated S6 and ERK (Fig. 5e and f), which provided a solid evidence that targeting MET was not a strategy for overcoming acquired resistance to afatinib in ESCC. Here, MET is linked to esophageal squamous cell carcinoma.